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Abstract
In our studies of ovarian cancer cells we have identified subpopulations of cells that are in a transitory E/M hybrid stage, i.e.
cells that simultaneously express epithelial and mesenchymal markers. E/M cells are not homogenous but, in vitro and in
vivo, contain subsets that can be distinguished based on a number of phenotypic features, including the subcellular
localization of E-cadherin, and the expression levels of Tie2, CD133, and CD44. A cellular subset (E/M-MP) (membrane E-
cadherin
low/cytoplasmic E-cadherin
high/CD133
high, CD44
high, Tie2
low) is highly enriched for tumor-forming cells and displays
features which are generally associated with cancer stem cells. Our data suggest that E/M-MP cells are able to differentiate
into different lineages under certain conditions, and have the capacity for self-renewal, i.e. to maintain a subset of
undifferentiated E/M-MP cells during differentiation. Trans-differentiation of E/M-MP cells into mesenchymal or epithelial
cells is associated with a loss of stem cell markers and tumorigenicity. In vivo xenograft tumor growth is driven by E/M-MP
cells, which give rise to epithelial ovarian cancer cells. In contrast, in vitro, we found that E/M-MP cells differentiate into
mesenchymal cells, in a process that involves pathways associated with an epithelial-to-mesenchymal transition. We also
detected phenotypic plasticity that was dependent on external factors such as stress created by starvation or contact with
either epithelial or mesenchymal cells in co-cultures. Our study provides a better understanding of the phenotypic
complexity of ovarian cancer and has implications for ovarian cancer therapy.
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Introduction
It has been suggested that tumor re-growth, as well as
chemotherapy resistance and metastasis, are dependent on a
small sub-population of cancer cells within the tumor that are
thought to represent cancer stem cells (CSCs). A defining hallmark
of stem cells, in both normal and malignant tissue, is the ability to
self-renew but simultaneously give rise to daughter cells that are
committed to differentiation into phenotypes that often cross
lineages. To achieve this, stem cells can undergo an asymmetric
cell division whereby they segregate cell fate determinants into
only one of the two daughter cells [1]. In adult mammals, stem
cells have been characterized for a number of tissues, including the
blood system, central nervous system, muscle, colon, breast, and
bone/cartilage.
For cancer stem cells in solid tumors, much can be learned from
studies of hematopoietic stem cells (HSC) for which it has been
shown that the transplantation of a single cell into a myeloablated
recipient can reconstitute the entire blood system. This definitive
HSC gives rise to a hierarchy of pluripotent progenitors that
become progressively restricted in their differentiation potential.
Leukemia is thought to originate either from HSCs that acquired
genetic or epigenetic changes and became partially differentiated
and tumorigenic, or from progenitors that acquired the capacity to
self-renew [2]. The existence of stem cells for certain types of
leukemia is strongly supported by lentiviral tagging of human
acute myelogenous leukemia cells and the observation of
individual clones present in NOD–SCID mice after serial
transplantation of the tagged cells [3]. Studies of leukemia stem
cells also indicated great phenotypic plasticity depending on the
stage of tumor growth, tumor microenvironment, and external
factors such as stress created by radio-or chemotherapy [2].
The presence of CSCs in solid tumors has been proposed for
human cancers including breast [4], brain [5], colon [6], head and
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cancer [13]. Solid tumor stem cells have been defined as ‘‘a small
subset of cancer cells within a cancer that constitute a reservoir of
self-sustaining cells with the exclusive ability to self-renew and to
cause the heterogeneous lineages of cancer cells that comprise the
tumor’’ [14]. Several cell surface markers, including CD24, CD44,
CD133, CD166, EpCAM, or dye efflux assays have been used to
sort populations of putative cancer stem cells from primary tumor
cultures or cell suspensions obtained from tumor biopsies. After
transplantation into immunodeficient mice, tumors form from
several hundred marker-positive cells, whereas for marker-
negative cells orders of magnitudes higher numbers are needed
to achieve the same frequency of tumor formation (for a review:
see [15]. Recently, using an improved xenotransplantation
technique, a study with human melanoma cells showed tumor
formation after inoculation of one tumor cell [16] and thereby an
important step towards the proof of CSC existence was made.
For most carcinomas, progression toward malignancy is
accompanied by loss of epithelial differentiation and a shift
towards a mesenchymal phenotype (EMT) [17]. EMT exacerbates
motility and invasiveness of many cell types and is often considered
a prerequisite for tumor infiltration and metastasis. EMT is
characterized by increased expression of mesenchymal markers
(vimentin, thrombospondin, N-cadherin, vitronectin), increased
expression of extracellular matrix compounds (collagen IV and
fibronectin), decreased expression of epithelial markers (E-
cadherin, Occludin, Desmoplakin, and Mucin1), altered location
of transcription factors (b-catenin, Snail, Slug, Twist, Sox 10, and
NFkB) and activation of kinases (ERK1, ERK2, and PI3K/AKT)
[17]. There are also numerous examples of advanced carcinomas
showing that mesenchymal cells can regain characteristics of
epithelial cells, a process called mesenchymal to epithelial
transition (MET) [18]. Apparently, the epithelial phenotype of
cancer cells and the ability to form physical barriers represent a
mechanism that restricts access of drugs, antibodies, or immune
cells to the sites of tumors. It has been speculated that both EMT
and MET involve cells in a metastable hybrid state, e.g. cells with
features of both epithelial and mesenchymal cells [19].
Our studies have focused on ovarian cancer. Ovarian cancer is
the fourth most common cancer in women and has the highest
mortality rate of all cancers of the female reproductive system.
Approximately 90% of human ovarian cancer arises from the
ovarian surface epithelium (OSE). The mesodermally derived
normal OSE shows epithelial and mesenchymal features, charac-
terized by the expression of both keratin and vimentin [20].
Interestingly, only low levels of E-cadherin are prominent in OSE
cells [21] and its expression is restricted to inclusion cysts and deep
clefts, remarkably to areas where early malignant events are
believed to occur [22]. The integrity of OSE layers is primarily
maintained by N-cadherin, which further highlights the epithelial/
mesenchymal phenotype in this tissue [23,24]. It is thought that
OSE cells adapt to changes in the cellular microenvironment by
transitions between epithelial and mesenchymal stages [20]. Such
abilities are usually restricted to immature, regenerating, or
neoplastic epithelia and therefore render a unique phenotypic
plasticity. It is thought that this plasticity lies at the origin of
ovarian cancer. Notably, ovarian carcinomas show a unique
feature when compared to other epithelial derived cancers.
Whereas the latter are characterized by the loss of epithelial
properties during tumor progression, elevated expression of E-
cadherin is observed for primary neoplastic ovarian epithelia [25].
However, this initial shift towards a more differentiated phenotype
early in tumor progression appears then to be followed by a
reacquisition of mesenchymal features in more advanced ovarian
tumors, involving a secondary loss of E-cadherin [26,27,28].
Interestingly, the epithelial/mesenchymal phenotype apparent in
OSE cells [29] is also found in the invasive front of colon [30] and
breast cancer [31], and in normal epidermal tissue during wound
repair [32].
In this study, we provide supporting data for one of the key
features of CSC, by demonstrating pluripotency, i.e. the ability to
give rise to phenotypically heterogeneous daughter cells. Our data
suggest that in ovarian cancer cells these features are intrinsically
linked with the phenomena of EMT and MET.
Results
Primary ovarian cancer cultures contain putative CSCs
We established 51 ovarian cancer cultures from biopsies/ascites
of grade III and IV carcinomas (Table S1). After digestion of
tumor biopsies with collagenase and trypsin, cell suspensions were
cultured in Mammary Epithelial Basal Medium supplemented
with EGF, insulin, hydrocortisone, bovine pituitary extract
(MEGM) and 1–2% FBS for up to 5 days. In order to confirm
their tumorigenic potential and to eliminate fibroblasts and
leukocytes, primary cells were injected into the mammary fat
pad of immunodeficient SCID-beige (C.B-Igh-1b/GbmsTac-
Prkdcscid-Lystbg N7) mice. Nine primary cultures formed
xenograft tumors after transplantation of 1610
6 cells (see Table
S1). Xenografts were then excised, digested with proteases and
cultured in MEGM with 10% FBS. For one culture, secondary
and tertiary xenografting was performed. Sections and suspensions
of original biopsies were named ovc-biopsy, ovc805-biopsy, etc;
primary cultures derived from patient biopsies were named
ovc316-PC, ovc805-PC, etc; sections or tumor suspensions from
xenograft tumors derived from primary cultures were named
ovc316-X, ovc805-X, etc; cultures derived from xenografts were
named ovc316-XC, ovc805-XC, etc.
Cultures contained different cell types, with clearly distinguish-
able subsets expressing different cancer markers (e.g. CA-125 or
CEA), which was reminiscent of the heterogeneity of tumor cells
seen from analysis of sections of the original tumor or the tumor
xenograft (Figure 1A, left three panels). Notably, tumor cell
heterogeneity was less pronounced in established ovarian cancer
cell lines such as SKOV3-ip1 (Figure 1A, right panel).
Considering the phenotypic heterogeneity of ovarian cancer,
the goal of our study was to isolate different cell subsets of primary
ovarian cancer cultures and test them for parameters that have
been associated with cancer stem cells, including proliferation,
pluripotency, and tumorigenicity. Light microscopy analysis of
xenograft cultures (e.g. ovc316-XC) revealed characteristic
epithelial subsets that contained polymorphic cells, which also
expressed large amounts of the extracellular matrix protein
laminin at the interphase to surrounding non-epithelial cells. In
culture the epithelial cellular subsets showed higher resistance to
trypsin treatment (Figure 1B). We separated the cells from early
passages (p,6) into two fractions based on trypsin resistance, and
tested their tumorigenicity in SCID-beige mice, but no difference
in tumor forming ability was observed (Figure 1B, right panel).
As done previously in an earlier study that analyzed the cellular
resistance to oncolytic adenoviruses [33], we established 100 clonal
cell cultures derived from early passage ovc316-XC cells. Clones
were expanded and analyzed for human-specific and cancer
markers (to exclude the presence of mouse stromal cells) as well as
epithelial and mesenchymal markers (Figure 1C). A total of 20% of
the resulting cultures were restricted to an epithelial phenotype (E-
cadherin positive; ‘‘epithelial clone’’), whereas 19% were mesen-
chymal (laminin positive, ‘‘mesenchymal clone’’). The remaining
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cells, in addition to cells that were positive for both epithelial and
mesenchymal markers (Figure 1C). We called these cells
epithelial/mesenchymal (E/M) hybrid cells. Clonal epithelial and
mesenchymal cultures had limited long-term proliferative potential
(20–25 passages mesenchymal, 20–40 passages epithelial cultures
respectively). Notably, during passaging, cells in one of the 20
epithelial clones lost membrane E-cadherin and claudin 7 and
acquired the mesenchymal transcription variant of p120 catenin
[33], indicating that it underwent an EMT (Figure S1).
Importantly, only cultures containing E/M cells were able to
form tumors in SCID-beige mice within 4 months when 10
5 cells
(passage 6) were injected (Figure 1D). Tumors displayed pheno-
typic heterogeneity, contained tumor stroma and were vascularized
(Figure 1E). Overall, histology of tumors derived from transplanted
clonalE/Mcellswassimilartothatofthepatienttumor(Figure1F).
Serial transplantation of cells derived from these tumors also gave
rise to new tumors (data not shown). Significantly, this study shows
that a single cell can form a clone that is subsequently able to form a
heterogeneous tumor. This indicates that the original cell was a
potential cancer stem cell, with the ability to differentiate, self-
renew, and form a tumor. Taken together, these data show that
primary ovarian cancer cultures are phenotypically heterogenous
and that tumor-initiating cells appear to havetraits of mesenchymal
and epithelial (E/M) cells.
Cells at the periphery of trypsin-resistant subsets contain
epithelial-mesenchymal hybrid (E/M) cells that co-stain
with stem cell markers
Having found a potential link between tumorigenic cancer stem
cell-like and epithelial/mesenchymal traits on clonal cultures from
ovc316-XC, we performed immunofluorescence analyses of the
primary ovarian cancer cultures (derived from biopsies or
xenografts) with a number of epithelial and mesenchymal markers
(Figure 2). We focused our analysis on cells that were isolated from
xenografts and had just (passage 0/1) or recently (passages 6–10)
adapted to tissue culture, and contained large proportions of
trypsin-resistant subsets. These subsets stainedpositive for epithelial
markers E-cadherin, claudin7 and EpCAM on lateral cell
membranes (Figures 2A, B). Cells surrounding epithelial subsets
were negative for these markers on their lateral membranes and
stained for mesenchymal proteins vimentin and laminin. Further
analysis for E-cadherin revealed phenotypic diversity within
ovc316-XC cultures. Two types of cells that localized E-cadherin
to their membranes were observed, membrane E-cadherin
high and
membrane E-cadherin
low (Figure 2A, lower panel, insert #2 and
3#). A third type of cells adjacent to membrane E-cadherin
high cells
contained clearly detectable E-cadherin in the cytoplasm/nucleus
(Figure 2A, lower panel, insert #2). Cytoplasmic E-cadherin
high
cells also stained positive for mesenchymal cell markers such as
laminin as well as caldesmon-1 (a myeloid marker), the endothe-
lial/endothelial progenitor markers CD31, and VCAM-1 (Figure
S2A). E-cadherin
high E/M-cells also expressed high levels of the
angiopoietin receptor Tie2 (Figure S2A, right panels). Notably,
Tie2 is a marker for hematopoietic stem cells that is also found on a
series of epithelial tumors [34,35].
Cultures at passage 0/1 generally showed higher overall
expression of epithelial and mesenchymal markers than cultures
in passages 6–10 and formed 3 dimensional cell conglomerates/
spheres containing E/M hybrid cells in highly proliferative areas
(Figure 2B). The E/M hybrid stage of cells (within spheres) was
confirmed by double staining with other epithelial markers
(EpCAM, claudin7) and mesenchymal markers (N-cadherin,
vimentin). Furthermore, spheres stained for EpCAM and the
mesenchymal stem cell marker CD44. Notably, most cells stained
for EpCAM, CD44, and vimentin (Figure 2B), suggesting that
EpCAM/CD44 signals underestimate the phenotypic diversity
within early passage ovarian cancer cells. The best discrimination
between different subsets was achieved with E-cadherin in
combination with a mesenchymal marker or CD44. Subsequently
we used this marker combination to characterize most of the
ensuing experiments. When analyzed for E-cadherin and the
putative cancer stem marker CD133, two subfractions of CD133
positive cells become apparent CD133
+/E-cadherin
high and
CD133
+/E-cadherin
low cells (Figure 2C). This observation further
supports the role of E-cadherin as a potential discriminatory
marker for cancer cell subsets. Cells within the E/M cell population
(particularly E-cadherin
low cells) also expressed other markers that
are characteristic of stem cells, including Nanog, Oct 4, and Sox2
(Figure S2B). E/M cells, particularly cells in spheres, were also
highly positive for the EMT inducers Snail, Twist and NGAL
(Figure 2D). Furthermore, we also found that cells that were low in
membrane-claudin 7 predominantly localize beta-catenin to the
cytoplasm/nucleus (Figure S2C). Transition of beta-catenin from
the cell membrane to the nucleus is an early event in EMT.
Overall, immunofluorescence studies indicate the existence of
two CD133
+ fractions; i) membrane E-cadherin
high and ii)
cytoplasmic E-cadherin
high/membrane E-cadherin
low cells. Cyto-
plasmic E-cadherin
high/membrane E-cadherin
low cells carry traits
of other cell lineages and therefore, most likely, represent primitive
progenitor cells or stem cells.
Change of phenotype, EMT and differentiation in vitro:
flow cytometry studies
To quantify numbers of cells with epithelial and mesenchymal
phenotypes in cultured cells, we employed flow cytometry and
Figure 1. Primary ovarian cancer cultures are heterogeneous and contain putative CSCs. A) Tumor biopsies and primary cultures stain
positive for ovarian cancer markers CA-125 (green) and CEA (red) and show higher heterogeneity than the established cell line SKOV3-ip1. Shown are
ovc316-biospy, ovc316-PC, and ovc316-X. Analysis of ovc1208-biopsy, ovc1208-PC, ovc0117-biopsy, ovc0117-PC, ovc100506-biopsy, and ovc100506-
PC revealed the same heterogeneity. B) Light microscopy of ovarian cancer culture ovc316-XC. The culture contains two distinct populations with
regards to trypsin sensitivity. Left panel: an early passage culture untreated (left), after 10 min trypsin treatment (center), and after trypsin-sensitive
cells were removed (right). Right panel: Tumor formation after transplantation of trypsin-resistant (TR) and trypsin-sensitive (TS) cells into SCID-beige
mice. Tumor formation was evaluated 3 months after inoculation. TIC TR: 1/185, TIC TS: 1/109. Chi-square=0.0524. C) Immunofluorescence analysis
for a human-specific mitochondrial (Mx) marker, the cancer marker CEA, the epithelial marker E-cadherin, and the mesenchymal marker laminin in
clonal cultures derived from ovc316-XC. Clonal cultures contain human cancer cells with either epithelial (upper panel), mesenchymal (center) or both
phenotypes (E/M hybrid clone, lower). D) Tumor-forming abilities after transplantation of 10
5 E, M, or E/M cells into SCID-beige mice. Tumor
formation was evaluated 4 months after inoculation. E) Xenograft tumors derived from E/M hybrid clones. The human origin of tumor cells is shown
by staining for a human specific mitochondria marker (green). Staining for the epithelial antigen AE1/3 and the tumor antigen CEA reveals
phenotypic heterogeneity in tumors that are derived from clonal E/M cultures. Laminin-expression is largely restricted to vascularized regions. F) H&E
staining of a xenograft derived from an ovc316-XC E/M clone and from a patient biopsy (ovc316-biopsy) showing that xenografts from resemble the
histology of human tumors in situ. The scale bar is 40mm.
doi:10.1371/journal.pone.0016186.g001
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well as monitoring for vimentin or CD44 marking cells with
mesenchymal attributes. Furthermore, to delineate phenotypic
changes overtime such as initiation of EMT, we analyzed different
passages of ovc316-XC cells (Figure 3). These studies revealed a
number of interesting observations. i) In tumor cell suspensions
Figure 2. Tumorigenic primary ovarian cancer cultures contain epithelial-mesenchymal hybrid (E/M) cells that co-stain with stem
cell markers. A) Analysis of E-cadherin (green) and Laminin (red) in ovarian cancer cultures. Magnification of marked areas is shown at the bottom:
A1) E-cadherin
negative cells express laminin. A2) Epithelial/mesenchymal (E/M) hybrid cells: E-cadherin
low cells show mainly cytoplasmic localization of
E-cadherin and high expression of laminin. E-cadherin
high cells contain elevated membrane E-cadherin levels and lower amounts of laminin. A3) E-
cadherin
positive cells have an increased cell size and maintain lower levels of clearly membrane-localized E-cadherin than E-cadherin
high cells. Laminin
expression is almost absent in E-cadherin
positive cells (upper right panel). B) Analysis for additional epithelial (green) and mesenchymal (red) markers
confirms the existence of E/M hybrid cells in ovc316-XC cultures. Epithelial marker
high cells are in close proximity to mesenchymal marker
high cells and
stain double positive in areas that contain spheres. In the left and middle panel, note that all cells are positive for vimentin and CD44. C) CD133 marks
areas that contain E-cadherin
high and E-cadherin
low cells. D) E-cadherin
high and E-cadherin
low cells show strong co-labeling with the EMT-inducers
Snail, Twist, and NGAL. The scale bar is 40mm. Shown are images from ovc316-XC. Immunofluorescence analysis of ovc0117-PC, ovc0122-PC,
ovc100506-XC, and ovc100728-XC revealed similar results.
doi:10.1371/journal.pone.0016186.g002
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were either E/M cells (EpCAM
high/Vimentin
high, EpCAM
high/
CD44
high) or E-cells (EpCAM
high/Vimentin
low, EpCAM
high/
CD44
low), however, at passage 1 only E/M cells could be
detected, indicating that the majority of cells obtained from
xenografts that adapt to tissue culture are E/M (Figure 3A). This
implies that, even at early passage, cultures do not adequately
reflect the cellular composition of the tumor in situ. Passage 1
contained EpCAM
high/CD44
high/Vimentin
high and EpCAM
high/
CD44
low/Vimentin
low cells. ii) Importantly during culture of cells
in MEGM containing growth factors/FBS (see passages 1, 5, 7, 20),
both the EpCAM
high/CD44
high/Vimentin
high or EpCAM
high/
CD44
low/Vimentin
low cell types disappeared and were replaced
by EpCAM
low/CD44
high/Vimentin
high cells. This demonstrates
that E/M cells differentiate into mesenchymal cells in vitro in an
EMT-like manner. iii) The majority of CD133
+ cells are E/M
hybrid cells. After passaging in culture ovc316-XC cells rapidly
lose CD133 expression concomitantly with the loss of epithelial
features.
We also found that for a number of passages starvation can stall
differentiation and the loss of the epithelial phenotype, while levels
of CD133 slightly decrease during this process (Figure 3B). Overall,
we found that primary ovarian cancer cultures show more sphere
formation when cultured without growth factors (Figure S3).
Having identified E-cadherin as a marker capable of differen-
tiating cellular subsets, we repeated flow cytometry analyses with
E-cadherin (Figure S3). Differentiation was also reflected by a
decrease in levels of E-cadherin and laminin after passaging.
Whereas low passage cultures contained high numbers of spheres,
E-cadherin
high cells, and excessive amounts of laminin, high
passage cells showed markedly reduced sphere growth and low
levels of these proteins while cell size increased (Figure 3C). This
was also confirmed in flow cytometry studies of passages 1, 3, and
7 (Figures S3A–C). These studies show that the mesenchymal (E-
cadherin
negative/low) sub-fraction increases during passaging and
concomitant EMT. CD133
+ cells were highly positive for CD44
(Figure S3A). We also analyzed membrane Tie2 in correlation to
E-cadherin (Figure S3B). By immunofluorescence analysis, Tie2
cells have an epithelial phenotype and are lower in CD44 than
CD133
+ cells. Notably, a correlation between E/M phenotype,
CD133/CD44-positivity, and tumorigenicity is also supported by
flow cytometry analysis of clonal cultures (Figure S3C). Only E/M
clones contained considerable amounts of CD133
+ cells with
elevated expression of CD44 (and as shown earlier, only E/M
clones formed tumors). The loss of ‘‘stem cell’’ features during
passaging is also reflected by reduction of the fraction of side
population (SP) cells from 7.860.5% at passage 3) to 2.160.3% at
passage 18 (Figure 3C). The SP cell phenotype has been associated
with cancer stem cells in previous studies of ovarian cancer [36].
Finally the loss of CD133
+ and E/M cells correlated with a
reduced ability to form tumors (Figure 3D).
Overall, we observed a striking difference of phenotypes
between cells in vivo and in vitro. Cells that adapted to tissue
culture were CD133
+ E/M cells. After passaging E/M cells
differentiate into mesenchymal cells in an EMT like manner. This
process is accompanied by a reduction of tumorigenicity.
Presence of E/M cell subsets in situ
Taking into consideration that ovarian cancer cultures,
particularly at late passages, only poorly reflect the phenotype of
tumors in situ, we focused our immunofluorescence and flow
cytometry analyses on sections of tumor biopsies or xenografts, or
cell suspensions obtained by collagenase digestion of tumors
(Figure 4). Immunofluorescence analyses of sections from
xenografts harvested at week 10 after tumor cell transplantation
(Figure 4) or sections of patient biopsies (Table S1, Figure S4)
showed that tumors in situ have clusters of E/M cells (EpCAM
+/
vimentin
+) as well as clusters of epithelial cells (E-cadherin
+/
Vimentin
2) (Figure 4A). In xenografts, nests of E/M and epithelial
cells were surrounded by layers of laminin. We also observed
costaining of E-cadherin and Tie2 (Figure 4B). CD133
high cells
(blue) are Tie2
low and E-cadherin
low (Figure 4B, lower panel). An
interesting pattern was observed when double staining with E-
cadherin and CD133 as CD133 positive cells were found at the
tumor periphery, in areas of active tumor growth (Figure S5A).
Notably not all CD133
+ cells were E/M cells. Within CD133
+
cells, we found two subsets of E/M cells as described earlier for the
in vitro studies (Figure 4C, larger magnification in Figure S5B).
Interestingly the CD133
high/membrane E-cadherin
low subset in
situ showed the presence of E-cadherin within cytoplasmic vesicles
more apparently than in vitro. The results obtained using xenograft
tumors were representative for staining of tumor sections from
nine different patients (Table S1, Figure S4).
Immunofluorescence analyses of tumors indicate the presence of
two E/M cell fractions: CD133
high/membrane E-cadherin
low/
cytoplasmic E-cadherin
high/Tie2
negative/low and CD133
intermediate/
membrane E-cadherin
high/cytoplasmic E-cadherin
negative/Tie2
high.
These immunohistological findings are supported by triple-color
flow cytometry analysis of ovc316-X xenografts for epithelial
markers (x-axis), mesenchymal features (y-axis), and for the cancer
stem cell marker CD133 (histogram plots) (Figures 4D–F).
Xenografts contain epithelial cells, epithelial/mesenchymal (E/M)
hybrid cells, and cells that are negative for all markers. CD133
+ cells
are almost exclusively in an E/M hybrid stage based on EpCAM/
CD44 analysis. CD133
high cells are EpCAM
high, CD44
high and
vimentin
low (Figure 4D). As in earlier studies, replacement of
EpCAM with E-cadherin in analyses reveals higher diversity within
xenografts (Figure 4E). CD44
high cells are E-cadherin
low/intermediate.
CD133
+ cells are divided into two clear sub-fractions. Fraction 1: E-
cadherin
low/intermediate/CD44
high and fraction 2: E-cadherin
high/
CD44
intermediate. CD133
high cells are E-cadherin
low/intermediate,
CD44
high and vimentin
low. Therefore CD44 and vimentin positivity
is inversely correlated. Tie2 marks cells that are E-cadherin
high/
CD44
intermediate and predominantly positive for vimentin
(Figure 4F). Tie2
2 cells are highly depleted for CD133 sub-fraction
2 and for E-cadherin
high/vimentin
high cells.
Because the phenotype of cultured ovarian cancer cells only
poorly reflects that of the tumor in situ, analysis of cell suspensions
of xenograft tumors without culturing is important. These studies
confirmed and extended our key conclusion from in vitro studies,
namely the existence of different subsets within CD133
+ cells:
CD133
high/membrane E-cadherin
low/intermediate/cytoplasmic E-
cadherin
high/Tie2
negative and CD133
intermediate/membrane E-cad-
herin
higgh/cytoplasmic E-cadherin
low/Tie2
positive.
Having identified several different cellular subsets in suspensions
from xenograft tumors, we attempted to isolate different fractions
using MACS or FACS for subsequent tumorigenicity and
pluripotency studies. Because of significant overlaps of cell
populations based on epithelial (E-cadherin/EpCAM) or mesen-
chymal markers (CD44/vimentin), we decided to use an indirect
approach to isolate E/M cell subfractions. As shown above, the
vast majority of E/M cells were CD133-postive. We therefore
isolated CD133-positive and CD133-negative cells using anti-
CD133 conjugated magnetic bead columns (Figure 5A) and cell
purity and viability was validated by flow cytometry. The
‘‘CD133
+’’ fraction contained 92.2% CD133-positive cells,
whereas the CD133-‘‘negative’’ fraction contained 5.4% of
CD133-positive cells. Tumorigenicity of CD133
+ and CD133
2
Ovarian Cancer Stem Cells
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16186Figure 3. E/M hybrid cells differentiate into mesenchymal cells in vitro.A ) Triple-color flow cytometry analysis of xenograft/biopsy cell
suspensions and cultured cells in vitro at different passages. Left panel: EpCAM/CD44/CD133. Right panel: EpCAM/vimentin/CD133. B) Passage 1 and
5 cells were subjected to 14 days of growth factor/FCS starvation and then analyzed by flow cytometry. Shown are data from ovc316-X and ovc316-
XC. The findings were confirmed on cell suspensions from biopsies and primary cultures (ovc100506-biopsy, ovc100506-PC, ovc100728-biopsy, and
100914). C) Immunofluorescence analysis of passage 3 and 18 cultures of ovc316-XC. Cells in early passages (passage 3) have elevated levels of E-
cadherin and laminin when compared to passage 18. Cells sizes are increased and sphere-growth in high cell densities is markedly reduced in high
Ovarian Cancer Stem Cells
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formed tumors after transplantation with 10 CD133
+ cells while
100 fold more CD133
2 cells were needed to achieve tumor
formation in 5 out of 10 mice (Figure 4A, lower panel). This
indicates that the CD133
+ cell fraction is enriched for tumor-
forming cells. Histology of CD133
+ and CD133
2 derived tumors
was identical, and tumors contained E/M (E-cadherin/laminin)
positive cells and were vascularized (Figure S6A). This could be as
a result of tumors from the ‘‘CD133
2’’ population being derived
from the 5.4% contaminating CD133-positive cells. Alternatively,
‘‘CD133
2’’ cells might be tumor-initiating, but at a lower
efficiency. Co-staining for the proliferation marker Ki-67 revealed
that both CD133
+ and CD133
2 cells contain similar numbers of
Ki-67 positive cells (Figure S6B).
Figure 4F shows that a significant subset of E/M cells were
positive for Tie2 (37% of CD44
+/E-cadherin
+ cells or 29.3% of
Vimentin
+/E-cadherin
+ cells) and that the vast majority of Tie2-
positive cells were E/M cells (90.7% of CD44
+/E-cadherin
+ and
73.6% of vimentin
+/E-cadherin
+ cells). Instrumental for a
separation of different E-cadherin fractions was the finding that
the low membrane E-cadherin levels correlated with low/absent
Tie2 expression. Column-isolated CD133
+ cells were therefore
further subdivided into Tie2
+ and Tie2
2 fractions using FACS
(Figure 5B). When transplanted into mice, tumor-forming ability
was clearly localized to CD133
+/Tie2
2 cells (Figure 5B, lower
panel). Immunofluorescence analysis of tumors derived from
transplanted CD133
+/Tie2
2 cells demonstrated that ,50% of
tumor cells were positive for Tie2 and expressed membrane E-
cadherin. Tie2 negative cells had cytoplasmic, punctuated E-
cadherin staining. This indicates that i) Tie2
2/membrane E-
cadherin
low cells transdifferentiate in vivo into epithelial Tie2
+/E-
cadherin
high cells (through MET) and ii) primitive Tie2
2/
cytoplasmic E-cadherin cells (i.e. potential cancer stem cells) are
maintained during tumor growth.
To consolidate these findings we performed studies with tumor
cells directly isolated from human ovarian cancer biopsies (see
Figures 5D–F). Biopsies were digested with collagenase/dispase
and cell suspensions were cultured in a rotating flask for 5 hours to
restore receptor expression. Cell suspensions were then subjected to
MACS for CD133 and FACS to separate CD133
+/Tie2
2 and
CD133
+/Tie2
+ cells (Figure 5D). Different numbers of CD133
+/
Tie2
2 and CD133
+/Tie
+ cells from biopsies were tested for tumor
formation (Figure 5E). Overall, engraftment of cells from biopsies
was less efficient than that of cells that had been cultured and
xenografted. Importantly, however, no tumor formation was
observed after transplantation of CD133
+/Tie2
+ cells, whereas 2
out of 15 or8 out of 15 mice developedtumors after transplantation
of 100 or 1,000 CD133
+/Tie
2 cells, respectively. These data
indicate that tumor-forming cells are enriched in the fraction of
CD133
high/Tie2
2/surface E-cadherin
low/intermediate cells.
In summary, based on the immunofluorescence and flow
cytometry data in vitro and in vivo, we tentatively propose two
phenotypically different subsets of CD133
+ E/M cells: i) E/M-MP
cells (CD133
high/membrane E-cadherin
low/intermediate/cytoplasmic
E-cadherin
+/Tie2
2). These cells are multipotent, having epithelial,
mesenchymal, and possibly other lineage traits. E/M-MP cells are
enriched for tumor-forming cells. ii) E/M-E cells (CD133
intermediate
/membrane E-cadherin
high/cytoplasmic E-cadherin
negative/Tie2
+).
We hypothesize that these cells are epithelial progenitor cells that
are less tumorigenic.
Phenotype studies on established ovarian cancer cell
lines in vitro and in vivo
We tested a series of human ovarian cancer cells lines, that are
widely used as models for testing new therapeutics (SKOV-3,
OVCAR3, and OVCAR5). SKOV-3 and OVCAR5 are tumor-
igenic while OVAR3 is not under the conditions used in this study.
With regards to marker expression, SKOV-3 and OVCAR5
grouped together and both lines expressed high levels of EpCAM
and CD44, but were nearly negative for surface CD133
(Figures 6A and B, upper panels). While in vitro the majority of
SKOV3 and OVAR5 cells were E-cadherin negative, the vast
majority of tumor cells in xenografts expressed high levels of E-
cadherin (Figures 6A and B, lower panels). In contrast, a different
marker phenotype was found for the non-tumorigenic line
OVCAR3 (Figure 6C). While these cells were also high for
EpCAM, CD44 levels were lower than in SKOV-3 and
OVCAR5. Most OVCAR3 cells were E-cadherin-positive, having
a more epithelial phenotype than SKOV3 and OVAR5 cells,
which apparently inversely correlated with tumorigenicity.
In agreement with our studies in ovc316-XC cells, we found E/
M hybrid cells (positive for EpCAM and/or E-cadherin, CD44
+,
and Tie2) in SKOV3 and OVC316-XC cells. We also confirmed
that upon transplantation, these cells acquire a more epithelial
phenotype, a process reminiscent of MET. In contrast to studies
with ovc316-XC cells, the ovarian cancer cell lines were almost
completely negative for surface CD133, however contained CD133
in cytoplasmic vesicles (Figure 6D), a phenomenon also recently
found in studies with osteosarcoma cell lines [37]. Cells with
cytoplasmic CD133 were also positive for Tie2, whereby Tie2
+/
CD133
+ double positive cells have lower levels of CD133
+ than
CD133
+/Tie2
2 cells (Figure S7). In summary, established ovarian
cancer cell lines displayed a hierarchical organization similar to
that found in primary cultures and their derived xenografts.
Maintenance of stem or progenitor phenotypes in vitro
and differentiation is dependent on substrate
E/M-MP cells are enriched for tumor-forming cells and express
both epithelial and mesenchymal markers (cytoplasmic E-
cadherin, CD44) as well as high levels of the putative cancer stem
cell marker CD133. These are all features that have been
associated with cancer stem cells in the past. Other critical
characteristics of stem cells in general are i) their multipotency. i.e
ability to differentiate into different lineages under certain
conditions, and ii) their ability to self-renew, i.e. maintain a subset
of undifferentiated cells during differentiation.
i) EMT in vitro and maintenance of E/M-MP and E/M-E
cells. Our finding that, during passaging, E/M cells give rise to
cultures that predominantly contain mesenchymal cells and lost
surface CD133 indicates differentiation (Figure 3). Notably, during
this process, a small subset of CD133
+ cells is maintained and this
subset expresses low to high levels of surface E-cadherin and high
levels of CD44. The maintenance of potential cancer stem cells also
explains the development of tumors after transplantation of passage
18 cells (see Figure 3D). Interestingly, when passage 18 cultures
were subjected to stress in the form of serum/growth factor
starvation, E/M-cells regain features of stem cells, particularly the
expression of nuclear Nanog, indicating a potential reversion of E/
M-E to E/M-MP cells (Figure S8). To gather further evidence for
differentiation of E/M subsets, we analyzed early passage ovc316-
passages. Percentage of side population (SP) positive cells are shown below. The scale bar is 40mm. D) Tumor formation after transplantation of
ovc316-XC passage 3 and 18 cells into SCID-beige mice (evaluated 4 months after inoculation). TIC p3: 1/110, TIC p18: 1/744. Chi-square: 0.245.
doi:10.1371/journal.pone.0016186.g003
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16186Figure 4. Phenotypic analysis of ovarian cancer xenografts and biopsies. A) Existence of E/M hybrid cells in situ. E-cadherin
+/vimentin
+ cells
are present biopsies and tumor xenografts. Shown are images of ovc316-biopsy and ovc316-X. Similar staining was found for ovc100506-biopsy/
ovc100506-X, ovc100728-biopsy/ovc100728-X, and ovc100914-biopsy/ovc100914-X. B) Correlation of E-cadherin (green) and Tie2 (red) positivity in
ovarian cancer biopsies. CD133
high cells (blue) are Tie2
low and E-cadherin
intermediate. Shown are images of ovc316-biopsy and ovc316-X. Similar
staining was found for ovc100506-biopsy/ovc100506-X, ovc100728-biopsy/ovc100728-X, and ovc100914-biopsy/ovc100914-X. C) CD133
high cells
have low levels of membrane E-cadherin. E-cadherin
high cells show punctated membrane CD133 staining. Shown are images of ovc316-biopsy and
ovc316-X. Similar staining was found for ovc100506-biopsy/ovc100506-X, ovc100728-biopsy/ovc100728-X, and ovc100914-biopsy/ovc100914-X. The
scale bar is 40mm. D–F) Triple-color flow cytometry analysis of ovc316-X for epithelial markers (x-axis), mesenchymal features (y-axis), and for cancer
stem cell marker CD133 (histogram plots). D) Xenografts contain epithelial cells, epithelial/mesenchymal (E/M) hybrid cells, and cells that are negative
for all markers. CD133
+ cells are almost exclusively in an E/M hybrid stage based on EpCAM/CD44 analysis. CD133
high cells are EpCAM
high, CD44
high
and vimentin
low. E) Replacement of EpCAM with E-cadherin reveals higher diversity within xenografts. CD44
high cells are E-cadherin
low/intermediate.
CD133
+ cells are divided into two clear sub-fractions. Fraction 1: E-cadherin
low/intermediate/CD44
high and fraction 2: E-cadherin
high/CD44
intermediate.
CD133
high cells are E-cadherin
low/intermediate, CD44
high and vimentin
low. The positivity of CD44 and vimentin correlates inversely. F) Tie2 marks cells
that are E-cadherin
high/CD44
intermediate and predominantly positive for vimentin. Tie2
2 cells are highly depleted for CD133 sub-fraction 2 and for E-
cadherin
cells/vimentin
high cells.
doi:10.1371/journal.pone.0016186.g004
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(Figure 7A). In agreement with earlier experiments, we found
high numbers of CD133
+ and Tie2
+ cells, whereby the majority of
CD133
+ and Tie2
+ cells are mutually exclusive. Tie2
+/CD133
+
double positive cells have lower levels of CD133
+ than CD133
+/
Tie2
2 cells. The vast majority of Tie2
+ cells stain positive for the
dead cell marker 7AAD after treatment with versene, indicating
their loss of resistance to anoikis after detachment, and therefore a
Figure 5. Tumor forming ability of CD133
+ subfractions. A) Validation of CD133
+ cell fractions obtained by column isolation. Purity of injected
cell fractions is shown. Cells used for transplantation were sorted by FACS and non-viable cells were excluded using SYTOX Green. Tumor-forming
cells are highly enriched in the CD133
+ cell fraction. Shown are studies with CD133
+ vs CD133
2 cells from eight pooled ovc316-X xenografts. (N=10
animals per group). Tumor formation was evaluated 4 months after inoculation. TIC CD133
+: 1/191, TIC CD133
2: 1/16725. Chi-square=8.25, p,0.01.
B) Column-isolated CD133
+ cells were further subdivided into Tie2
+ and Tie2
2 fractions by FACS. Cells used for transplantation were sorted by FACS
and non-viable cells were excluded using SYTOX Green. Tumor-forming abilities are more pronounced in CD133
+/Tie2
2 cells. Shown are data from
transplantation of CD133
+/Tie2
+ vs CD133
+/Tie
2 cells from ovc316-XC (N=10). TIC CD133
+/Tie2
+: 1/10593, TIC CD133
+/Tie2
2: 1/650. Chi-square: 6.74,
p,0.01. C) Immunofluorescence analysis of tumors that developed after transplantation of CD133
+/Tie
2 cells. D and E) Analysis of fractions derived
from patient biopsies. D) Schematic of cell isolation. E) Tumor formation after transplantation of CD133
+/Tie2
2 and CD133
+/Tie2
+ cells derived from
ovc100506-biopsy. Tumor formation was evaluated 3 months after inoculation. TIC CD133
+/Tie2
2: 1185, TIC CD133
+/Tie2
+: n.a.
doi:10.1371/journal.pone.0016186.g005
Ovarian Cancer Stem Cells
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16186Ovarian Cancer Stem Cells
PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16186higher degree of differentiation. Viable cells show higher mean
fluorescence of CD44 and CD133. All attached cells are positive for
the cell proliferation marker Ki-67.
ii) MET in vivo. Another indication of differentiation comes
from xenotransplantation studies. Cells used for transplantation
were in passage 1 to 3 and the vast majority of cells were E/M
cells. Importantly, the tumors that were derived from these cells
were comprised of clusters of E/M cells (E-cadherin
+/vimentin
+
and EpCAM
+/vimentin
+) as well as clusters of epithelial cells
(EpCAM
high or Ecadherin
high). The presence of epithelial cells in
tumors, i.e. a cell type that was absent in the inoculated cells,
indicate that E/M cells differentiate towards epithelial cells in vivo,
in a process reminiscent of MET. Maintenance and differentiation
of cancer stem cells is also supported by the finding that
transplantation of Tie2
2 cells resulted in tumors consisting of
Tie2-positive epithelial cancer cells and Tie2
2 cells (representing
less differentiated cells or cancer stem cells).
iii) Differentiation of E/M-MP cells depending on
substrate (Figure 7B). To further support differentiation of
E/M cells in vitro, we isolated CD133
high cells from tumor
xenografts and sorted them for viable CD133
high/E-cadherin
low
and CD133
high/E-cadherin
high cells. When cultured at low cell
densities, sorted CD133
high/E-cadherin
high and CD133
high/E-
cadherin
low cells differentiate into similar cell populations with a
mainly epithelial phenotype and low CD133 levels. We then co-
cultured the two different cell fractions with either epithelial or
mesenchymal cells. For the latter we used epithelial (E) and
mesenchymal (M) clonal cultures (see Figure 1C). Cell membrane
dye PHK26 was used to discriminate substrate E or M cells
(PHK26 positive) and cells derived from the sorted CD133
+
populations (PHK26 negative). When co-cultured with E or M
cells at a ratio of 1:10, CD133
high cells differentiate into epithelial
or mesenchymal cells, depending on the provided environment.
Notably, sorted CD133
+/E-cadherin
high generated more E-
cadherin-positive cells than sorted CD133
+/E-cadherin
low cells
when cultured among M cells (Figure 7B).
A gain in epithelial features, particularly in E-cadherin is thought
to occur early in ovarian cancer development. We therefore studied
the phenotype of non transformed ovarian surface epithelial cells.
Importantly, a similar subset of CD133
+/E-cadherin
+/CD44
+ also
exists in early passage ovarian surface epithelial (OSE) cells
(Figures 7C and D). This subset comprises less than 1% of the
total culture. In striking difference to ovc316-XC cells, E-cadherin
levels for the vast majority of OSE cells are low. Tie2
+ cells in OSE
and ovarian cancer cultures are enriched for E-cadherin and show
lower mean fluorescence for CD44 than CD133
+ cells.
Activation of EMT pathways during passaging of ovc316-
XC cells
The finding that E/M cells undergo EMT in vitro is supported
by the analysis of signaling pathways using Western blot with
antibodies to key kinases (Figures 8A). It is generally accepted that
EMT is characterized by the activation of several kinases,
including ERK1, ERK2, and PI3K/AKT [17]. Xenograft tumors
contain high amounts of E-cadherin and CD133, which decrease
after culturing. Concomitant with a loss of these markers is a
switch from phophorylated p38 to phophorylated ERK44/42.
Adaption to tissue culture (compare ovc316-X tumor and ov316-
XC p1) is also associated with ERK44/42 and cRAF1 activation.
The decrease in the phosphorylated form of the stress kinase p38
can most likely be explained by the loss of ECM and integrin
signaling when cells are removed from tumor xenografts.
The activation of pathways during in vitro passaging is further
corroborated by studies using specific phosphokinase inhibitors
(Figures 8B–D). The inhibition of Raf, MKK, or JNK significantly
decreases proliferation rates of ovc316-XC cells. The inhibition of
p38 increases the number of viable cells. Flow cytometry shows the
presence of the two E/M-MP and E/M-E (E-cadherin
high/
CD44
high or E-cadherin
low/CD44
high) fractions (Figure 8D). Inhi-
bition of JNK, Raf, and growth factor starvation decreases the
mean level of CD44.Growth factor starved and JNK-inhibitedcells
are highly epithelial and CD133 positive indicating that JNK
pathways are also involved in mediating EMT. In the presence of
JNK inhibitor, cells differentiate into epithelial cells/progenitors
(CD44
low, CD133
intermediate) instead. The inhibition of Raf and
MKK/ERK highly depletes ovc316-XC cultures for E-cadher-
in
high/CD44
high cells, indicating that Raf and ERK are important
for proliferation and maintenance of undifferentiated epithelial
cells (E-cadherin
high/CD44
high). The inhibition of p38increases the
mean level of CD44, demonstrating a role for p38 in the
maintenance of undifferentiated epithelial cells (E-cadherin
high/
CD44
high). Taken together, pathway and inhibitor analyses support
the presence of EMT in vitro upon culturing of ovarian cancer cells.
Discussion
For this study we investigated the characteristics of human
ovarian cancer cells derived from patient tumor biopsies. Our
conclusions are based on the analysis of 14 different biopsies, 10
primary ovarian cancer cultures, 4 xenografts and cultures thereof.
In the different cellular subsets found within these tumors we
noticed a number of phenotypic features, which are summarized
in Figure 9A. Our best understanding of the interconnections
between these diverse subsets in relation to their relative
mesenchymal or epithelial status is described in Figure 9B. In
primary ovarian cancer cultures and tumors in situ we found cells
that were in an epithelial and mesenchymal (E/M) hybrid stage.
Based on the differences in the levels of the markers E-cadherin,
CD133, Tie2 and CD44, we defined different subsets within E/M
cells that differed in pluripotency and tumorigenicity. A multip-
otent, tumorigenic E/M cell subset (E/M-MP), that fits the
profile of true cancer stem cells, had high levels of cytoplasmic
E-cadherin, membrane CD133 and membrane CD44. This
subset also expressed markers of other lineages, including CD31,
VCAM-1 and caldesmon, and displayed features of stem cells,
including the presence of nuclear-localized Nanog. MACS and
FACS based separation of this subset was possible based on the
presence of CD133 and CD44, and the absence of Tie2. Several
lines of data indicate that these E/M-MP cells are multipotent. We
found that transplantation of CD133
high/membrane E-cadher-
in
low/intermediate/cytoplasmic E-cadherin
+/Tie2
2 resulted in tu-
mors consisting of membrane E-cadherin
high/Tie2-positive cells,
indicating that tumor growth in vivo is driven by E/M-MP cells,
which give rise to an E/M subset, with more dominant epithelial
Figure 6. Characterization of cellular phenotypes within ovarian cancer cell lines in vivo and in vitro. A–C) Flow cytometry analysis for
indicated markers in ovarian cancer cell lines. Upper panels show cellular phenotypes of cultures in vitro, lower panels show phenotypes of cells in
vivo (xenografts). In vitro cultures of SKOV3-ip1 (A) and OVCAR-5 (B) contain high numbers of CD44
+ cells and are enriched for E-cadherin negative
cells. Tumor xenografts are highly epithelial. C) Non-tumorigenic OVCAR-3 cells have low CD44 levels and a highly epithelial phenotype in vitro. D)
Immunofluorescence analysis of indicated ovarian cancer cell lines for CD133. Note that SKOV3-ip1 cells have low CD133 surface levels by flow
cytometry, but contain high amounts of CD133 in the cytoplasm. The scale bar is 40mm.
doi:10.1371/journal.pone.0016186.g006
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+ cells. A) Viability of different subsets. Low passage ovc316-XC cells contain high numbers of
CD133
+ and Tie2
+ cells. Tie2
+/CD133
+ double positive cells have lower levels of CD133
+ than CD133
+/Tie2
2 cells. The vast majority of Tie2
+ cells stains
positive for the dead cell marker 7-AAD after treatment with versen. Viable cells show higher mean fluorescence of CD44 and CD133. All attached
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all mesenchymal and stem cell traits, and that had lost the ability
to form tumors (when isolated in vitro in the form of clonal cultures)
(Figure 9B, left scheme). Therefore, tumor growth in xenografts
appears to involve processes reminiscent of MET. Corresponding
MET-inducing signals might emanate from the tumor-associated
Figure 8. Impact of MAP kinases on proliferation and differentiation in CD133
+ derived cells. A) Western blot analysis of E-cadherin,
CD133 and the MAPK pathway in ovc316-XC tumor xenografts, low passage (p1), high passage (p20), and in clonal epithelial and mesenchymal
cultures. Xenograft tumors contain high amounts of E-cadherin and CD133, which decrease after culturing. Concomitantly with a loss of these
markers occurs a switch from phophorylated p38 to phophorylated ERK44/42. B) Impact of MAPK pathway inhibitors on proliferation. Cells (p7) were
passaged in the presence of inhibitors for 21 days. C) Bright field analysis of ovc316-XC cells cultured in the presence of indicated inhibitors after 21
days. The scale bar is 40mm. D) Flow cytometry analysis of ovc316-XC cells cultured in the presence of indicated inhibitors after 21 days (N=3).
doi:10.1371/journal.pone.0016186.g008
cells are positive for the cell proliferation marker Ki-67. B) CD133
+ cells isolated from ovc316-XC tumor xenografts adapt to their environment. When
cultured at low cell densities, sorted CD133
+/E-cadherin
high and CD133
+/E-cadherin
low cells differentiate into similar cell populations with an epithelial
phenotype. When co-cultured with clonal ovc316-XC epithelial or mesenchymal cultures (ratio 1:10), CD133
+ cells differentiate into epithelial or
mesenchymal cells, depending on the environment. Cell membrane dye PHK26 was used to discriminate between clonal cells (PHK26 positive) and
cells derived from the CD133
+ population (PHK26 negative). Cells were cultured for 7 days. C and D). Similarities between primary ovarian cancer
cells and normal ovarian surface epithelial cells (OSE). Early passage OSE cells show high similarities with early passage ovarian cancer cultures. OSE
cultures are low in E-cadherin and are CD133
+. CD133
+ cells within OSE and ovarian cancer cultures are enriched in cells positive for E-cadherin and
CD44. Tie2
+ cells in OSE and ovarian cancer cultures are enriched for E-cadherin and show lower mean fluorescence for CD44 than CD133
+ cells.
doi:10.1371/journal.pone.0016186.g007
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in vitro cultures), and/or be caused by the 3-dimensional
organization of tumor cells.
In contrast, we found in vitro indication of E/M-MP cells
differentiating into mesenchymal cells, through the process of
EMT (Figure 9B, right scheme). Of all the cells in suspensions
derived from patient biopsies or xenografts, only E/M hybrid cells
(E/M-MP and rare E/M-E) adapted to tissue culture and were
found in early cell passages. After passaging these E/M cells
differentiated into mesenchymal cells that lacked epithelial or stem
cell markers and tumor forming ability. Our findings are
suggestive for EMT, however could theoretically also be due to
selective expansion of specific cell subsets. The following data
support EMT rather than selective expansion: i) E/M cells express
EMT inducers such Snail, Twist and NGAL (Figure 2D), ii) in
vitro culturing is associated with the activation of EMT pathways
(ERK1, ERK2, and PI3K/AKT) during culturing and passaging
(Figure 8), iii) Studies with clonal cultures showed that epithelial
cells can lose membrane E-cadherin and claudin 7 and acquire the
mesenchymal transcription variant of p120 catenin (Figure S1),
and iv) the same CD133
+ E/M cells give rise to either epithelial or
mesenchymal cells when cultured on epithelial or mesenchymal
substrates, respectively (Figure 7B). We speculate that activation of
EMT programs in vitro is facilitated by the disruption of cell-cell
Figure 9. Cellular subsets in human ovarian cancer. A) Summary of phenotypic markers found in different ovarian cancer subsets. B)
Interconnection between different subsets. (Description in text).
doi:10.1371/journal.pone.0016186.g009
Ovarian Cancer Stem Cells
PLoS ONE | www.plosone.org 15 January 2011 | Volume 6 | Issue 1 | e16186adherens junctions, due to culture medium supplements such as
EGF, and the cell-ECM adhesions mediated by integrins.
Interestingly, E/M cells isolated from xenografts seem to be
initially primed towards epithelial differentiation for a number of
passages, as supported by several experiments (Figure 3, Figure
S3A). Here, the maintenance of high CD133 levels and self-
renewal of undifferentiated cells depends on high cell densities
(Figure 3, Figure S3A). The accelerated cell division of
undifferentiated E/M cells might be supported by the high
production of extracellular matrix proteins, observed in early
passages (Figure 3C), whereas low cell densities of E/M-MP cells,
or growth among more differentiated cells, enforces differentiation
and the rapid loss of CD133 (Figures 7A,B). Moreover, the
phenotypic plasticity of E/M-MP cells and their daughter cells
highly depends on the provided cellular environment. During in
vitro passaging, EMT-inducing events trigger the generation of E-
cadherin
negative cells, which is accompanied by the loss of CD133
and lowered secretion of ECM components (Figure 3). The
culturing of E/M-MP cells among mesenchymal cells accelerates
the loss of E-cadherin, whose maintenance on the cell surface
requires homophilic intercellular connection.
Our data also indicates that the composition of E/M subsets
fluctuates when cultures are exposed to stress such as starvation.
Cultures that were subjected to starvation become enriched for
cells with stem cell features (e.g. presence of Nanog in nuclei, shift
from membrane E-cadherin to nuclear E-cadherin). This indicates
that E/M-E cells can revert to E/M-MP cells and vice versa in vitro
and potentially in vivo (dashed arrows, Figure 9B). Furthermore,
our in vitro data suggests the existence of committed epithelial
progenitor cells (membrane E-cadherin
high, CD133
intermediate/low,
CD44
intermediate, Tie2
+) that lost resistance to anoikis and the
ability to revert into E/M-E and E/M-MP cells. We also speculate
that these cells might be able to lose E-cadherin and convert,
through a secondary EMT, into more differentiated mesenchymal
cells (Figure 9B, dotted arrow). A similar process is thought to
occur late in ovarian cancer development and during ovarian
cancer metastasis. As discussed earlier, subfractions and processes
similar to those described by us for primary ovarian cancer cells
appear to exist in the development of ovarian cancer.
A central conclusion from our studies of ovarian cancer is the
existence of E/M hybrid cells. Our data suggest that specific E/M
subsets are pluripotent, i.e. have the ability to transdifferentiate
into epithelial and mesenchymal cancer cells through MET and
EMT, respectively. EMT in the context of the CSC concept in
breast cancer was recently reported by Weinberg’s group. They
found that induction of EMT through over-expression of Snail or
Twist in human mammary epithelial cells caused these cells to
exhibit cell surface markers similar to those of cancer stem cells,
such as CD44
high/CD24
low [38]. These and other studies on
prostate cancer [39] indicate that EMT-like events, i.e. the
generation of mesenchymal-like cells, are associated with an
increase in tumor-forming capacity. In contrast, we found in our
studies with ovarian cancer cells that cultures, which predomi-
nantly contain mesenchymal cells are less tumorigenic than E/M
cultures from which they are derived from. We speculate that this
discrepancy is due to intrinsic differences between ovarian cancer
and other epithelial cancers [25].
We also found that E/M-MP cells have endothelial traits
(CD31, VCAM-1). Notably, two recent publications have shown
that glioma stem cells can differentiate into endothelial cells and
generate tumor vasculature [40,41].
Furthermore, our data suggest that ovarian cancer displays both
a spatial and temporal heterogeneity involving tumor cell subsets
that differ in their ability to form tumors and differentiate. Ovarian
cancers are composed of tumor-driving E/M-MP cells as well as
non-tumorigenic differentiated cancer cells that compose the bulk
of cells in a tumor. This observation has implications for tumor
therapy, which is often directed toward markers found on
epithelial cancer cells (e.g. Her2/neu, EGFR, FGFR).
Future studies will have to focus on the delineation of the
genetic and epigenetic differences between cellular subsets. These
studies will also clarify the currently widely discussed question
about whether tumor heterogeneity is due to distinct clones from
different CSCs or whether CSCs, like their normal counterparts,
are multipotential. A conclusion from our studies is that the
heterogeneity of malignant cells present in ovarian cancer is the
result of the multipotential capacity of E/M-MP cells for
differentiation.
The concept of a hierarchy of pluripotent progenitors that
fluctuates during tumor growth and under selective pressure is not
without precedents. Studies on leukemia-initiating cells indicate
that there is probably not a single cancer stem cell, but different
groups of stem cells that can change their phenotype depending on
external factors. Studies in xenograft models have shown that
multiple subclones capable of leukemia initiation arise in parallel,
and that most of the clones that initially form a tumor do not
survive long term and do not have the capacity for self-renewal
because they disappeared upon retransplantation [3].
Until recently, it was thought that tumor-initiating cells are a
rare subpopulation in cancers. Nevertheless, improvements in
xenotransplantation models and the use of syngeneic mouse models
of breast cancer have shown that the number of tumor-initiating
cells is much larger [16]. It is still elusive whether these findings can
be generalized to other cancers, including ovarian cancer. Our
findings that large percentages of E/M cells have tumor-forming
abilities support this. Notably, the CSC hypothesis does not rely on
the size of the cancer-initiating population, but more importantly
on the presence of a hierarchy of tumor-forming, multipotent cells.
CD133 has been used to enrich for cells with tumor-initiating
ability from a variety of human solid tumors from the brain,
prostate, liver, breast and colon [42], but there are also studies that
question the value of CD133 as a putative CSC marker,
particularly in colon cancer and melanoma [16]. Few attempts
have been undertaken to further characterize the CD133
+
population of cancer cells. In human breast cancer cell lines, it
has been found that an ALDEFLUOR-positive CD44
+ subpop-
ulation of CD133
+ cells was more enriched for tumor-initiating
cells than ALDEFLUOR-negative CD44
2/CD133
+ cells [42]. In
osteosarcoma, a CD133
+/ABCG2
+/SP
+ subset was enriched for
cells with CSC features, such as the formation of spheres/clusters
in serum-free medium with high clonogenic efficiency [37]. A
clonal cell expansion model in glioblastoma recently revealed
multiple tumor-initiation populations with different potential for
hierarchical differentiation and aggressiveness. These populations
were either positive or negative for CD133, whereby one fraction
of CD133 negative cells could also give rise to CD133
+ cells [43].
Our study confirms earlier reports that in ovarian cancer the
CD133
+ population is enriched in tumor-forming cells when
compared to CD133
2 cells [11,44]. We also found that in biopsies
from different ovarian cancer patients (Figure S4) and xenograft
tumors (Figure 3), CD133
+ cells comprise a large fraction (,30%)
of tumor cells. This determines that further differentiation of cells
within the population of CD133
+ cells is needed. Our study is the
first to utilize E-cadherin and Tie2 as a marker to isolate different
CD133
+ fractions from tumor material. Potentially, other
endothelial markers (e.g. VCAM-1) could be used for a similar
purpose. Notably, even though CD133
+/Tie2
+ fail to efficiently
initiate tumor growth in mice, it remains questionable whether
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The positivity for proliferation marker Ki-67 among CD133
+ cells
in xenografts would argue against this (Figure S6B). Furthermore,
it is possible that tumors arise at a later time point, since primary
ovarian cancer cells from patient biopsies display much greater
heterogeneity than established cancer cell lines. Ultimately, the
analysis of tumor-forming abilities most likely resembles only a
‘‘snapshot’’ of tumors or tumor cell cultures at time of analysis.
Such analyses might therefore underestimate the potential of less
tumorigenic cells that have the potential for de-differentiation
under different conditions.
In our study the loss of CD133 was linked to EMT in in vitro
cultures. Surface CD133
+ mesenchymal cells were rarely observed,
whereas mesenchymal cells often harbored CD133 in the
cytoplasm. Notably, CD133 has been recognized as a marker
for developing epithelium [45]. Therefore, the isolation of cells
from (mainly mesenchymal) in vitro cultures based on surface
CD133 might not assess the complete tumor-forming population.
An important conclusion from our study is that CD133 mainly
marks a population of E/M hybrid cells, which is adaptable to
different conditions and able to differentiate into either epithelial
or mesenchymal cells depending on the provided environment.
We therefore suggest that CD133 should only be used in
combination with epithelial and mesenchymal markers in order
to identify and study tumor-initiating cells within ovarian cancers.
The overall picture of potential cancer stem cells that we
obtained from our study is relatively complex. It involves the
existence of subsets of tumor forming cells with distinct differen-
tiation potential. The composition of these subsets is transitory, and
can shift bi-directionally, depending on external conditions and the
stage of tumor growth. The understanding of this phenotypic
complexity has important implications for ovarian cancer therapy.
Methods
Tissue Culture
Ovarian cancer biopsies were provided by the Pacific Ovarian
Cancer Research Consortium (POCRC) Specimen Repository
without any cconfidential information which would serve to
identify a patient (Fred Hutchinson Cancer Research Center IRB
protocol # 6289). Tumor tissue from biopsies was dissected into
4mm pieces and digested for 2 hours at 37uC with 1mg/ml
collagenase/dispase (Roche) and 0.1mM CaCl2 (Sigma) in RPMI
1640 (Gibco). This was followed by incubation with versene
(Gibco) (1:1 vol/vol) for 1 hour. The protease digestion was
stopped by the addition of FBS (Gibco) to a final concentration of
10%. Cells were passed through a 70 mm cell strainer (BD Falcon)
using the plunger of a 5ml syringe (Becton Dickinson). The cell
strainer was washed with 25ml RPMI and the total flow-through
was pelleted. The pellet was resuspended in 5ml RPMI/10%FBS
with 1mg/ml DNaseI (Roche) and incubated for 30 min at 37uC.
Cells were pelleted again and subjected to a ficoll gradient (10ml
underlay, Stem Cell Technologies) separation step if high amounts
of erythrocytes were observed. The resulting cultures were kept in
MEGM (Lonza) at low serum levels (1–2%) and in high cell
densities, in order to minimize fibroblast growth. Clonal ovc316-
XC cultures were established as published previously [33]. Clones
were established by limited dilution (0.5 cells seeded per well in a
96 well plate) to ensure single cell suspension. Single cell plating
was confirmed by light microscopy and wells containing more than
one cell were excluded from further culturing. Further rounds of
subcloning of clonal E/M cultures yielded the same secondary and
tertiary clonal cultures with hybrid E/M phenotype and tumor-
forming ability. SKOV3-ip1, OVCAR-3, and OVCAR-5 cells
were cultured in MEGM/DMEM (Lonza/Gibco, 50%/50% v/v)
supplemented with 10% FBS and 1% Penicillin/Streptomycin.
Inhibitors
CD133
+ cells were isolated by column isolation (Miltenyi
Biotec). A total of 2.5610
5 CD133
+ cells were seeded in 12 well
plates (BD Falcon) and subsequently treated with inhibitors diluted
in fresh MEGM medium. All inhibitors were purchased from
Calbiochem and used in the following concentrations: Raf1
inhibitor (20 mM), U0126 (40 mM), p38 inhibitor III (10 mM), JNK
inhibitor II (100 nM). Inhibitors were replaced with fresh medium
every 48 hrs and cells were passaged (1:2), when the first
experimental culture (p38 inhibitor-treated) reached 100%
confluence. Cells were analyzed by flow cytometry after 21 days.
In order to evaluate proliferation rates, 10% (v/v) of each
individual experimental setup from passage 3 were seeded into 96
well plates in triplicate. Cells were further cultured in the presence
of inhibitors for 3 days prior to readout by MTT assay.
MTT assay
MTT assays were carried out in 96 well plates in triplicate. A
total of 15ml of a stock solution of 5mg/ml 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (Sigma) per well was
applied for 2 hrs. Medium was aspirated, formazide crystals were
disolved in DMSO, and absorbance was measured at 495 nm
using a plate reader. The percentage of viable cells is relative to
mock treated cells.
Flow cytometry
Adherent cells were detached from tissue culture plates by
treatment with Versene (Gibco) for 30–60 min. Cells were then
transferred into 15ml tubes (BD Falcon) and washed with RPMI
1640 supplemented with 10% FBS. Cell pellets were resuspended
in ice-cold PBS with 1% FBS in order to block unspecific antibody
binding. Then 2610
5 cells were incubated with antibodies in 5ml
round bottom tubes (BD Falcon) in a total of 100ml for 45 min on
ice. All subsequent incubation steps were carried out in the dark.
Cells were washed with 3 ml PBS+1%FBS and centrifuged at
400g for 5 min at 4uC. After surface antigen staining, cells were
fixed with 4% paraformaldehyde for 15 min on ice. Following a
PBS+1%FBS wash, cells were either subjected to flow cytometry
analysis or prepared for intracellular antigen staining (vimentin,
Ki-67) by treatment with 0.1% Triton6100 (Sigma) for 15 min at
room temperature. If needed, fluorophor-labeled secondary
antibodies were used against the appropriate host. Samples were
filtered (70mm, Becton Dickinson) and then analyzed using either a
BD FACSCanto or BD FACScalibur flow cytometer (Becton
Dickenson). Unspecific background of individual channels was
determined with isotype controls and color compensation was
done on single color-stained samples. Dead cells were excluded
with 7AAD (Invitrogen). Figures were generated using FlowJo for
Macintosh (Tree Star, Inc.).
Animal studies
All experiments involving animals were conducted in accor-
dance with the institutional guidelines set forth by the University of
Washington and the Federation of European Laboratory Animal
Science Associations for the care and use of laboratory animals.
The studies were approved by the University of Washington
Institutional Animal Care and Use Committee (protocol # 3108-
01) and the Danish Cancer Society (protocol #2009-19). All mice
were housed in specific-pathogen-free facilities. To establish
subcutaneous tumors, CD17-SCID-beige mice were injected in
Ovarian Cancer Stem Cells
PLoS ONE | www.plosone.org 17 January 2011 | Volume 6 | Issue 1 | e16186the mammary fat pad with 1610
5 tumor cells or indicated cell
numbers using a Matrigel (BD Biosciences)/MEGM (50ml/50ml)
mix. Immunofluorescence analyses of tumor sections was per-
formed as described elsewhere [46].
Limiting dilution analyses were carried out using Extreme
Limiting Dilution Analysis (ELDA) [47]. Estimated numbers for
frequency of tumor-initiating cells (TIC) were calculated by
confidence intervals. Tumor-initiating cell populations were
compared by likelihood ratio tests and obtained chi-square and
p-values are indicated.
Cell sorting
Cell sorting was performed on a pool of 8 freshly dissected
ocv316-X tumor xenografts. CD133
+ and CD133
2 cells were
isolated using the CD133/2-biotin antibody and anti-biotin
microbeads according to the manufacturers protocol (Miltenyi
Biotec). Three separate MACS LS columns were consecutively
used to isolate high purity fractions. Following isolation, cells
were either incubated with Tie2-PE antibodies or isotope
control. Cell separation and cell number sorting was done with
a BD Cytopia Influx. Dead cells were excluded with SYTOX
Green (Invitrogen). Cells were sorted into ice-chilled 96well round-
bottom plates with a Matrigel/MEGM (50ml/50ml) mix and
subsequently injected into mice. Purity of sorted fractions was
confirmed using the BD FACScalibur flow cytometer. For
separation of CD133
high/E-cadherin fractions the CD133/1-PE
and E-cadherin-APC antibodies were used with the Beckman-
Coulter MoFlo XDP. Viable cells were isolated by sorting for
7AAD negative events. Additional studies were performed
with tumor cell suspensions isolated from patient biopsies.
Tumors were microdisected, homogenized and digested with
collagenase/dispase as elsewhere http://www.miltenyibiotec.
com/download/protocols_gentlemacs_en/1624/gentleMACS-
tumor_human-01.pdf. To re-express cell surface molecules, tumor
cells were cultured in suspensions in a rotating tube for 5 hours and
then subjected to MACS and FACs as described above.
Co-culture of CD133
high cells with epithelial or
mesenchymal cells
1610
4 sorted CD133
high/E-cadherin
high or CD133
high/E-
cadherin
low cells were cultured either alone or in co-culture with
1610
5 epithelial or mesenchymal cells derived from clonal
ovc316-XC cells in 6 cm dishes (Nunc). Clonal ovc316-XC
cultures were labeled using the PHK26 membrane stain (Sigma)
prior to co-culturing. Cell-labeling was carried out according to
the manufacturers protocol with an extended labeling time of
15 min followed by three wash steps.
Western Blot
Xenograft tumor tissue was dissected, manually homogenized
(glass homogenizer) and incubated for 30 min in protein lysis
buffer (20mM Hepes (pH 7.5), 2mM EGTA, 10% glycerol, 1%
Triton6100, 1mM PMSF, 200mMN a 3VO4 [all Sigma], and
protease inhibitors [Complete Protease Inhibitor Cocktail, Roche])
on ice. Confluent cultured cells were washed with ice-cold PBS
twice and then lysed for 30 min in protein lysis buffer on ice. After
30 seconds of sonication (Branson Sonifier 250, intensity 4 of 10)
on ice, samples were pelleted (10 min, 4uC, 15,000 RPM,
Eppendorf table centrifuge) and protein containing supernatant
stored at 280uC. A total of 15mg of total protein was used for
Western blotting. Protein samples were boiled (5 min, 95uC) and
separated by polyacrylamide gel electrophoresis using 4–15%
gradient gels (BioRad) followed by transfer onto nitrocellulose
membranes according to the supplier’s protocol (Mini ProteanIII,
BioRad). Membranes were blocked in PBS, 0.1% Tween20 (PBS-
T, Sigma) +5% dry milk powder (BioRad). Incubation times for
primary and secondary antibodies were 2 hours and 1 hour at
room temperature, respectively. Antibodies were diluted in PBS-T
+2% dry-milk powder. Membranes were washed 5 times in PBS-T
between antibody incubations, and films were developed using
ECL plus (Amersham).
Immunofluorescence
Cells were cultured in 8 chamber glass slides (BD Falcon),
washed twice with ice-cold PBS and then fixed with methanol/
acetone (1:1 vol/vol) for 15 min at 4uC. After fixation cells were
washed with PBS twice and blocked with 500ml PBS/2% dry-milk
powder for 20 min at room temperature. Antibody staining was
performed in 100ml PBS for 90 min at 37uCo r4 uC overnight. If
needed, fluorophor-labeled secondary antibodies directed against
the appropriate host, were applied for 45 min at room
temperature after 3 washes with PBS. After a further 3 washes
with PBS, glass slides were mounted using VECTASHIELD with
DAPI (Vector Labs). All immunofluorescence pictures were taken
with a Leica DM1000 microscope featuring a Leica DFC FX
camera (Leica Microsystems). Tumor sections of patient material
or xenografts were snap frozen embedded in OCT compound
(Tissue-Tek) on dry ice. OCT embedded tissues were then stored
at 280uC and equilibrated to 220uC for at least 1 hour prior to
sectioning. Tumor tissue was sliced (8 microns) using a Leica CM
1850 cryostat (Leica Microsystems) and then transferred onto
Superfrost slides (Fisher Scientific). Slides were fixed in acetone
(Fisher Scientific) for 10 min at 220uC. After two rinses with PBS
(Sigma) slides were blocked with 2% milk powder (BioRad) in PBS
for 20 min at room temperature.
Antibodies
All antibodies and the dilutions used in this study are detailed in
Table S2.
Supporting Information
Figure S1 Transdifferentiation of clonal epithelial cells
into mesenchymal cells. A) Epithelial clone derived from
ovc316-XC at passage 8 and passage 20 stained for the epithelial
markers E-cadherin and Claudin 7. B) Passage 20 cells stained for
the mesenchymal marker N-p120. The scale bar is 40mm.
(PDF)
Figure S2 Characterization of E/M hybrid cells. A)E -
cadherin
high cells contain low amounts of CD31, caldesmon, and
VCAM-1, whereas E-cadherin
low cells stain highly positive for
these markers. B) Analysis of pluripotency markers. E-cadherin
low
cells express high levels of nuclear-localized Nanog and Oct4.
Most cells in ovc316 cultures contain high amounts of nuclear
Sox2. C) Correlation of membrane-bound beta-catenin (green)
and claudin 7 (red). Cells low on membrane-claudin 7 predom-
inantly localize beta-catenin to the cytoplasm/nucleus. Shown are
images from ovc316-XC. D) Staining for human mitochondrial
marker. Immunofluorescence analysis of ovc0117-PC, ovc0122-
PC, ovc100506-XC, and ovc100728-XC revealed similar results.
(PDF)
Figure S3 Characterization of different cellular pheno-
types ovarian cancer cultures. A) Analysis of E-cadherin
(x axis), CD44 (y axis), and CD133 (histogram). Shown are density
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+ sub-
fraction within the culture (right panel). CD133
+ cancer stem-like
cells are highly positive for CD44 and are divided into epithelial
and mesenchymal phenotypes. The mesenchymal sub-fraction
enriches during passaging and concomitant EMT in culture
ovc316. The total amount of CD133 dramatically decreases after
passaging. Shown are studies with ovc316-XC. B) Analysis of E-
cadherin (x axis), CD44 (y axis), and Tie2 (histogram). Shown are
density blots of the whole culture (left panel) and of the Tie2
+ sub-
fraction within the culture (right panel). Tie2
+ progenitor cells
have an epithelial phenotype and are lower in CD44 levels than
CD133
+ cells. Shown are studies with ovc316-XC. C) Flow
cytometry analysis of clonal ovc316-XC cultures. Non-tumorigen-
ic epithelial and mesenchymal clones are low on CD133.
Tumorigenic E/M hybrid cultures contain CD133
+ cells of
epithelial and mesenchymal phenotypes that are highly positive
for CD44. D) Sphere formation after growth factor starvation in
primary ovarian cancer cultures from different biopsies. Primary
cultures were grown In MEBM medium for 5 days. Shown are
studies with four primary cultures.
(PDF)
Figure S4 E/M cells subsets in biopsies from ovarian
cancer patients. A) Sections from patient biopsies were stained
for the epithelial marker E-cadherin and the mesenchymal marker
Vimentin. B and C) Sections from patient biopsies were stained
for E-cadherin and CD133 (B) or E-cadherin and Tie2 (C).
CD133
+ areas with differential E-cadherin staining are marked.
Shown are sections of ovc1208-biopsy, ovc0122 biopsy, and
ovc0117-biopsy. Immunofluoresence analysis of ovc1123-biopsy,
ovc0111-biopsy, ovc0116-biopsy, ovc123-biopsy, and ovc100506-
biopsy resulted in similar staining.
(PDF)
Figure S5 Sections of ovc31-X xenografts. A) Global view
of a xenograft tumor assembled from different images. B) Higher
magnification of an ovc316-X xenograft section to visualize two
different CD133
+ subsets, including areas with membrane E-
cadherin and areas with punctated cytoplasmic E-cadherin.
(PDF)
Figure S6 Analysis of CD133 fractions. A) Sections of
tumors derived from sorted CD133
+ and CD133
2 cells. B) Flow
cytometry analysis for differentiation and proliferation markers.
CD133
+ and CD133
2 cells within ovc316-X xenograft tumors are
positive for Ki-67. CD133
2 cells contain higher amounts of Ki-67
negative cells than the CD133
+ cell fraction.
(PDF)
Figure S7 Ovarian cancer cell lines contain CD133
+ and
Tie2
+ cells. The majority of CD133
+ and Tie2
+ cells are
mutually exclusive. Tie2
+/CD133
+ double positive cells have
lower levels of CD133
+ than CD133
+/Tie2
2 cells. A) SKOV3-ip1
cells. B) OVCAR-5 cells. C) OVCAR-3 cells
(PDF)
Figure S8 Expression of E-cadherin and stem cell
markers CD133 and Nanog after growth factor/serum
starvation of passage 18 ovc316-XC cells.
(PDF)
Table S1
(PDF)
Table S2
(PDF)
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